Sihuan Pharma (00460) Schedules 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend

Bulletin Express

Mar 19

Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 00460) has announced that its board of directors will convene on 31 March 2026. Key agenda items include:

• Approval and publication of the consolidated annual results for the financial year ended 31 December 2025.

• Deliberation and, if deemed appropriate, approval of a final dividend for shareholders.

The meeting will be chaired by Dr. Che Fengsheng, who serves as Chairman and Executive Director. The board currently comprises five executive directors—Dr. Che Fengsheng, Dr. Guo Weicheng, Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili—alongside three independent non-executive directors: Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.

The company notified the Hong Kong market of the scheduled meeting via an exchange filing dated 19 March 2026. No additional financial details were disclosed in the announcement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1161078965"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161078965\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161078965?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161078965","market":"hk","top_or_hot":-1,"title":"Sihuan Pharma (00460) Schedules 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend","media":"Bulletin Express","content":"<p>Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 00460) has announced that its board of directors will convene on 31 March 2026. Key agenda items include:</p>\n<p>• Approval and publication of the consolidated annual results for the financial year ended 31 December 2025.</p>\n<p>• Deliberation and, if deemed appropriate, approval of a final dividend for shareholders.</p>\n<p>The meeting will be chaired by Dr. Che Fengsheng, who serves as Chairman and Executive Director. The board currently comprises five executive directors—Dr. Che Fengsheng, Dr. Guo Weicheng, Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili—alongside three independent non-executive directors: Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.</p>\n<p>The company notified the Hong Kong market of the scheduled meeting via an exchange filing dated 19 March 2026. No additional financial details were disclosed in the announcement.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sihuan Pharma (00460) Schedules 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSihuan Pharma (00460) Schedules 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-19 16:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 00460) has announced that its board of directors will convene on 31 March 2026. Key agenda items include:</p>\n<p>• Approval and publication of the consolidated annual results for the financial year ended 31 December 2025.</p>\n<p>• Deliberation and, if deemed appropriate, approval of a final dividend for shareholders.</p>\n<p>The meeting will be chaired by Dr. Che Fengsheng, who serves as Chairman and Executive Director. The board currently comprises five executive directors—Dr. Che Fengsheng, Dr. Guo Weicheng, Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili—alongside three independent non-executive directors: Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.</p>\n<p>The company notified the Hong Kong market of the scheduled meeting via an exchange filing dated 19 March 2026. No additional financial details were disclosed in the announcement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00460","symbol_name":"四环医药","start_time":0,"source_url":"","article_id":"1161078965","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161078965","pubTimestamp":1773909795,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 00460) has announced that its board of directors will convene on 31 March 2026. Key agenda items include: • Approval and publication of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00460":"四环医药"},"translate_title":"四环医药(00460)定于2026年3月31日召开董事会批准2025财年业绩并考虑末期股息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1},"content_text":"Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 00460) has announced that its board of directors will convene on 31 March 2026. Key agenda items include:\n• Approval and publication of the consolidated annual results for the financial year ended 31 December 2025.\n• Deliberation and, if deemed appropriate, approval of a final dividend for shareholders.\nThe meeting will be chaired by Dr. Che Fengsheng, who serves as Chairman and Executive Director. The board currently comprises five executive directors—Dr. Che Fengsheng, Dr. Guo Weicheng, Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili—alongside three independent non-executive directors: Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.\nThe company notified the Hong Kong market of the scheduled meeting via an exchange filing dated 19 March 2026. No additional financial details were disclosed in the announcement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}